Quantcast
 
New book by Larry Connors Click here Improve your trading - See how


 

Zacks Analyst Blog Highlights: Jones Soda Co., Raytheon Co., Georgia Gulf Corp., Avis Budget Group Inc. and Acorda Therapeutics Inc.

Wed. September 24, 2008; Posted: 06:00 AM
Stocks RSS
CHICAGO, Sep 24, 2008 (BUSINESS WIRE) -- RTN | Quote | Chart | News | PowerRating -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Jones Soda Co. (Nasdaq: JSDA), Raytheon Co. (NYSE: RTN), Georgia Gulf Corp. (NYSE: GGC), Avis Budget Group Inc. (NYSE: CAR | Quote | Chart | News | PowerRating) and Acorda Therapeutics Inc. (Nasdaq: ACOR).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday's Analyst Blog:

Jones Soda Trying to Energize

Headquartered in Seattle, Washington, Jones Soda (Nasdaq: JSDA | Quote | Chart | News | PowerRating) develops, manufactures, markets, and distributes premium soda products under the Jones Soda, Jones Energy (citrus energy drink), Jones Organics (ready-to-drink organic tea), Jones Naturals (non-carbonated juice & tea), Jones Pure Cane Soda (premium soda), Jones 24C (enhanced water beverage), and WhoopAss (citrus energy drink) brands.

The last six quarterly earnings reports were negative surprises. Throughout last year, management pared revenue guidance from the initial estimation of +50%; actual gross revenues increased only 5% and net revenues increased only 2%. However, the stock has discounted the majority of the negative developments. The rating is a Hold.

Raytheon a Buy, But With Risks

Raytheon Company (NYSE: RTN | Quote | Chart | News | PowerRating) is the one of the largest aerospace and defense companies in the U.S., with a well-diversified line of military products, including missiles, radars, sensors, surveillance and reconnaissance equipment, communication and information systems, naval systems, air traffic control systems, and technical services.

Going forward, however, concerns about long-term growth of defense spending in the face of continuing budget deficits and risks related to the company's program execution remain significant risks. Accordingly, we note a bias to outperformance and maintain our BUY recommendation on RTN common stock with a six-month target price of $63.50.

Georgia Gulf Chasm Widens

Georgia Gulf Corporation (NYSE: GGC | Quote | Chart | News | PowerRating) is a leading North American manufacturer and marketer of two integrated chemical product lines, chlorovinyls and aromatics. Its key products are chlorine, caustic soda, vinyl chloride monomer (VCM), polyvinyl chloride (PVC), cumene, phenol and acetone. Under the Royal Group brand, Georgia Gulf manufactures a complete line of custom and other vinyl-based building and home improvement products.

Demand for the company's products is also expected to remain weak due to the downturn in the US housing and auto markets. Moreover, the company may need to sell its assets to comply with the debt covenants. As a result, we have a Sell rating with a target of $2.50.

Avis Near-Term View Fuzzy

Avis Budget Group (NYSE: CAR | Quote | Chart | News | PowerRating) is comprised of the vehicle rental operations of Avis Rent-A-Car, Budget Rent-A-Car, and Budget Truck Rental. Avis is the world's second largest general-use car rental business with over 2,200 locations in the United States, Canada, Australia, New Zealand and the Latin American/Caribbean region.

The near-term outlook for the Avis Budget Group is difficult to ascertain. The truck rental business is experiencing pricing pressure and the economy is weakening. Revenue enhancement and cost cutting initiatives have been implemented that should fuel significant financial improvements.

Acorda Therapeutics Overvalued

Acorda Therapeutics (Nasdaq: ACOR | Quote | Chart | News | PowerRating) is a biotechnology company whose mission is to develop and market therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. Core technologies developed by Acorda for SCI and MS have potentially broad applicability for other neurologic conditions.

The company released full data from its phase III MS-F204 clinical trial this month. The data is consistent with previous phase III data on Fampridine-SR showing improvement in walking speed and leg strength for the responder population.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com

Zacks.com Mark Vickery Web Content Editor 312-265-9380 Visit: www.zacks.com

For full details on Acorda Therapeutics Inc (ACOR) click here. Acorda Therapeutics Inc (ACOR) has Short Term PowerRatings of 8. Details on Acorda Therapeutics Inc (ACOR) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [ACOR]
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.